BeiGene | Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer

⟵ Back to Search Results

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer

Beigene Study ID

BGB-A317-214

ClinicalTrials.gov ID

NCT05116085

China Drug Trials ID

CTR20212779

Sex: All

Age: 18 Years / N/A

No Study Documents

Sex: All

Age: 18 Years / N/A

No Study Documents